https://www.selleckchem.com/products/yo-01027.html
05). The mean time of hospital discharge of patients and return to baseline health was significantly shorter in the intervention group compared to the control group (p 0.05). No deaths and adverse events were observed in both groups. Adjuvant use of melatonin has a potential to improve clinical symptoms of COVID-19 patients and contribute to a faster return of patients to baseline health. Adjuvant use of melatonin has a potential to improve clinical symptoms of COVID-19 patients and contribute to a faster return of patients to base
Like
Comment
Share
